We discuss with Michael Wechsler (National Jewish Health, Denver, CO, USA) the clinical evidence supporting the use of dupilumab in patients with asthma and specifically the major findings from the long-term safety evaluation of dupilumab in the LIBERTY ASTHMA TRAVERSE trial (NCT02134028).
1. What are the major unmet needs in the biologic treatment of moderate to severe asthma? (0:17)
2. Could you tell us a little about dupilumab, its mechanism of action and its advantages compared to other biologic therapies? (1:30)
3. What clinical evidence supports the efficacy and safety of dupilumab? (3:20)
4. Could you give us a brief overview of the LIBERTY ASTHMA TRAVERSE study and its major findings? (5:05)
5. Which patients are most likely to benefit from dupilumab therapy? (6:50)
Disclosures: Michael Wechsler has acted as a consultant for Sanofi Aventis, Regeneron, Amgen, AstraZeneca, Teva, GSK, Novartis, Genentech, Equillium, Cohero and Boehringer Ingelheim.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020.
Share this Video
Related Videos In Asthma
Whitney Stevens, AAAAI 2021: Treatment of Aspirin-Exacerbated Respiratory Disease (AERD)
It was a pleasure to speak with Professor Whitney Stevens (Northwestern University Feinberg School of Medicine, Chicago, IL, US) around aspirin desensitisation in aspirin-exacerbated respiratory disease. ‘Aspirin desensitization for AERD in 2020: An update from the AERD work group.’ was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March […]
Klaus Rabe, AAAAI 2021 – The Efficacy of Dupilumab in GINA-Defined Difficult To-Treat Type 2 Asthma Patients (Part 2)
Dr Klaus Rabe (Lung Clinic Großhansdorf and The University of Kiel, Germany) spoke with touchRESPIRATORY around his post-hoc analysis of the LIBERTY ASTHMA QUEST study (Clinical Trial Identifier: NCT02414854). The abstract ‘Dupilumab Efficacy in GINA-Defined Difficult To-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST Study.’ (ABSTRACT NUMBER: 183) was presented at the American […]
Klaus Rabe, AAAAI 2021 – The Efficacy of Dupilumab in GINA-Defined Difficult To-Treat Type 2 Asthma Patients (Part 1)
It was a pleasure to speak with Dr Klaus Rabe (Lung Clinic Großhansdorf and The University of Kiel, Germany) around the rationale for the use of dupilumab in GINA-defined difficult to-treat type 2 asthma patients (Clinical Trial Identifier: NCT02414854). The abstract ‘Dupilumab Efficacy in GINA-Defined Difficult To-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!